A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament "hook" effect

Journal of Neuroscience Methods

Volumn 195, Issue 2, 2011, Pages 143-150

  Lu, Ching Hua ^a   Kalmar, Bernadett ^a   Malaspina, Andrea ^b   Greensmith, Linda ^a   Petzold, Axel ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Motor neuron disease; Neurodegeneration; Protein aggregates; Protein biomarker; SOD1 mice

Indexed keywords

BARBITAL; CHELATING AGENT; EDETIC ACID; NEUROFILAMENT PROTEIN; UREA;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID CULTURE; CONTROLLED STUDY; DENSITOMETRY; DILUTION CURVE; ENZYME LINKED IMMUNOSORBENT ASSAY; GIANT AXONAL NEUROPATHY; HEREDITARY MOTOR SENSORY NEUROPATHY; IMMUNOASSAY; IMMUNOBLOTTING; INCUBATION TIME; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PLASMA; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; QUALITATIVE ANALYSIS; ROOM TEMPERATURE;

AGE FACTORS; ANIMALS; CHELATING AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EDETIC ACID; EGTAZIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOASSAY; MICE; MICE, TRANSGENIC; MUTATION; NEUROFILAMENT PROTEINS; PLASMA; SUPEROXIDE DISMUTASE; UREA;

EID: 78751705193     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.11.026     Document Type: Article

References (46)

1. Ashbury A.K., Gale M.K., Cox S.C., Baringer J.R., Berg B.O. Giant axonal neuropathy: a unique case with segmental neurofilamentous masses. Acta Neuropathol 1972, 80:237-247.
2. Blennow K., Hampel H., Winer M., Zetterberģ H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6(3):131-144.
3. Boylan K., Yang C., Crook J., Overstreet K., Heckman M., Wang Y., et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 2009, 11(5):1182-1191.
4. Cairns N.J., Zhukareva V., Uryu K., Zhang B., Bigio E., Mackenzie I.R., et al. Alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol 2004, 164:2153-2161.
5. Charrié A., Charrière G., Guerrier A. Hook effect in immunometirc assays for prostate-specific antigen. Clin Chem 1995, 41(3):480-481.
6. Cohlberg J.A., Hajarian H., Tran T., Alipourjeddi P., Noveen A. Neurofilament protein heterotetramers as assembly intermediates. J Biol Chem 1995, 270(16):9334-9339.
7. David D.C., Ollikainen N., Trinidad J.C., Cary M.P., Burlingame A.L., Kenyon C. Widespread protein aggregation as an inherent part of aging in C. elegans. PLos Biol 2010, 8(8):e1000450.
8. Fabrizi G.M., Cavallaro T., Angiari C., Bertolasi L., Cabrini I., Ferrarini M., et al. Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E. Neurology 2004, 62:1429-1431.
9. Forno L.S., Sternberger L.A., Sternberger N.H., Strefling A.M., Swanson K., Eng L.F. Reaction of Lewy bodies with antibodies to phosphorylated and non-phosphorylated neurofilaments. Neurosci Lett 1986, 64:253-258.
10. Frieze T.W., Mong Dp., Koops M.K " Hook Effect" in prolactinomas: case report and review of literature. Endocr Pract 2002, 8(4):296-303.
11. Furuya Y., Cho S., Ohta S., Sato N., Kotake T., Masai M. High dose hook effect in serum total and free prostate specific antigen in a patient with metastatic prostate cancer. J Urol 2001, 166:213.
12. Hisanaga S., Hirokawa N. Molecular architecture of the neurofilament II. Reassembly process of neurofilament L protein in vitro. J Mol Biol 1990, 211:871-882.
13. Ishii T., Haga S., Tokutake S. Presence of neurofilament protein in Alzhermer's neurofibrillary tangles (ANT). An immunofluorescent study. Acta Neuropathol 1979, 48:105-112.
14. Iqbal K., Liu F., Gong C.X., Alonso Adel C., Grundke-Iqbal I. Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 2009, 118(1):53-69.
15. Jassam N., Jones C.M., Briscoe T., Horner J.H. The hook effect: a need for constant vigilance. Ann Clin Biochem 2006, 43:314-317.
16. Julien J.P. A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. Biochem Cell Biol 1995, 73:593-597.
17. Kalmar B., Novoselov S., Gray A., Cheetham M.E., Margulis B., Greensmith L. Late stage treatment with arimoclomol delays disease progression and prevents protein aggregation in the SOD1 mouse model of ALS. J Neurochem. 2008, 107(2):339-350.
18. Kovacech B., Skrabana R., Novak M. Transition of tau protein from disordered to misordered in Alzheimer's disease. Neurodegenerative Dis 2010, 7(1-3):24-27.
19. Kushkuley J., Chan W.K., Lee S., Eyer J., Leterrier J.F., Letournel F., et al. Neurofilament cross-bridging competes with kinesin-dependent association of neurofilaments with microtubules. J Cell Sci 2009, 122(19):3579-3586.
20. Kushkuley J., Metkar S., Chan W.K., Lee S., Shea T.B. Aluminum induces neurofilament aggregation by stabilizing cross-bridging of phosphorylated c-terminal sidearms. Brain Res 2010, 1322:118-123.
21. Leboeuf R., Langlois M-F., Martin M., Ahnadi C.E., Fink G.D " Hook Effect" in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature. J Clin Endocrinol Metab 2006, 91(2):361-364.
22. Maccioni R.B., Farías G., Morales I., Navarrete L. The revitalized tau hypothesis on Alzheimer's disease. Arch Med Res 2010, 41(3):226-231.
23. Manetto V., Sternberger N.H., Perry G., Sternberger L.A., Gambetti P. Phosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 1988, 47:642-653.
24. Miles L.E.M., Lipschitz D.A., Bieber C.P., Cook J.D. Measurement of serum ferritin by a 2-site immunoradiometric assay. Anal Biochem 1974, 61:209-224.
25. Perrot R., Berges R., Bocquet A., Eyer J. Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration. Mol Neurobiol 2008, 38:27-65.
26. Petzold A., Keir G., Green A.J., Giovannoni G., Thopmson E.J. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003, 278:179-190.
27. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005, 233(1-2):183-198.
28. Petzold A, Tisdall M, Girbes AR, Martinian L, Thom M, Kitchen N, Smith M. In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study. Brain in press.
29. Plikaytis B.D., Holder P.F., Pais L.B., Maslanka S.E., Gheesling L.L., Carlone G.M. Determination of parallelism and nonparallelism in bioassay dilution curves. J Clin Microbiol 1994, 32(10):2441-2447.
30. Saha S., Das K.P. Unfolding and refolding of bovine a-crystallin in urea and its chaperone activity. Protein J 2007, 26(5):315-325.
31. Schmidt M.L., Murray J., Lee V.M., Hill W.D., Wertkin A., Trojanowski J.Q. Epitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol 1991, 139(1):53-65.
32. Shaw G., Yang C., Ellis R., Anderson K., Mickle J.P., Scheff S., et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 2005, 336(4):1268-1277.
33. Shea T.B. Triton-soluble phosphovariants of the high molecular weight neurofilament subunit from NB2a/d1 cells are assembly-competent. Implications for normal and abnormal neurofilament assembly. FEBS Lett 1994, 343:131-136.
34. Shefner J.M. Motor unit number estimation in human neurological diseases and animal models. Clinical Neurophysol 2001, 112:955-964.
35. Sternberger N.H., Sternberger L.A., Ulrich J. Aberrant neurofilament phosphorylation in Alzhermer disease. Proc Natl Acad Sci USA 1985, 82:4274-4276.
36. St-Jean E., Blain F., Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol 1996, 44:305-309.
37. Su J.H., Cummings B.J., Cotman C.W. Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res 1996, 739:79-87.
38. Tokutake S. On the assembly mechanism of neurofilaments. Int J Biochem 1990, 22(1):1-6.
39. Troy C.M., Stefanis L., Greene L.A., Shelanski M.L. Mechanisms of neuronal degeneration: a final common pathway?. Adv Neurol 1997, 72:103-111.
40. Tuner M.R., Kiernan M.C., Leigh P.N., Talbot K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol 2009, 8:94-109.
41. Uchikado H., Shaw G., Wang D.S., Dickson D.W. Screening for neurofilament inclusion disease using alpha-internexin immunohistochemistry. Neurology 2005, 64:1658-1659.
42. Winhammar J.M.C., Rowe D.B., Henderson R.D., Kiernan M.C. Assessment of disease progression in motor neuron disease. Lancet Neurol 2005, 4:229-238.
43. Wong N.K.Y., He B.P., Strong M.J. Characterization of neuronal intermediate filament protein expression in cervical spinal motor neurons in sporadic amyotrophic lateral sclerosis (ALS). J Neuropathol Exp Neurol 2000, 59(11):972-982.
44. Yabe J.T., Chylinski T., Wang F.S., Pimenta A., Katter S.D., Linsley M.D., et al. Neurofilaments consist of distinct populations that can be distinguished by C-terminal phosphorylation, bundling, and axonal transport rate in growing axonal neuritis. J. Neurosci 2001, 21(7):2195-2205.
45. Yabe J.T., Wang F.S., Chylinski T., Katchmar T., Shea T.B. Selective accumulation of the high molecular weight neurofilament subunit within the distal region of growing axonal neuritis. Cell Motil Cytoskeleton 2001, 50:1-12.
46. Zangi R., Zhou R., Berne B.J. Urea's action on hydrophobic interactions. J Am Chem Soc 2009, 131(4):1535-1541.